BPC January 14 update

GeoVax GOVX -11% Private placement; Theseus THRX +23% Stake

Price and Volume Movers

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) shares closed up 23% at $11.73 after the investment manager OrbiMed Advisors disclosed the purchase of approximately 44.7K of company shares, increasing its stake to 16.9 million shares.

GeoVax Labs, Inc. (NASDAQ: GOVX) announced that it has entered into an agreement to raise approximately $10 million through the private placement of 707,484 shares of common stock, and 2,360,000 pre-funded warrants. Shares closed down 11% at $2.77.

CureVac NV (NASDAQ: CVAC) shares closed down 9% at $24.48 after the company said dievini Hopp Biotech Holding GmbH and the German government amended an agreement related to their CureVac stakes. The amendment involves topics including voting, board appointments and holding periods.

Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares closed up 8% at $5.70. Adagio recently announced findings that showed that its ADG20 has neutralization activity against Omicron.

Pfizer Inc. (NYSE: PFE) announced that the FDA approved CIBINQO (abrocitinib) to treat moderate-to-severe atopic dermatitis (AD). Shares closed down 1% at $54.95.

AbbVie (NYSE: ABBV) announced that the FDA approved RINVOQ (upadacitinib) to treat moderate to severe atopic dermatitis in adults and children 12 years of age and older. Shares closed up 2% at $135.87.

SVB Leerink maintained Molecular Partners (NASDAQ: MOLN) with an Outperform and raised the price target from $35 to $42. Shares closed up 13% at $31.89.

Advancers

CompanyPriceChange
ARDS
Aridis Pharmaceuticals Inc.
$1.60+0.27  +20.30%
CINC
CinCor Pharma Inc.
$18.20+2.13  +13.25%
RVLP
RVL Pharmaceuticals plc
$1.20+0.11  +10.09%
ITCI
Intra-Cellular Therapies Inc.
$42.66+3.79  +9.75%
GMDA
Gamida Cell Ltd.
$3.24+0.28  +9.46%
HILS
Hillstream BioPharma Inc.
$3.36+0.23  +7.35%
KPTI
Karyopharm Therapeutics Inc.
$8.28+0.55  +7.12%
CNTX
Context Therapeutics Inc.
$2.10+0.13  +6.60%
LABD
Direxion Daily S&P Biotech Bear 3X Shares
$45.71+2.71  +6.30%
BDSI
BioDelivery Sciences International Inc.
$3.36+0.18  +5.66%

Decliners

CompanyPriceChange
IMMX
Immix Biopharma Inc.
$4.51-0.91  -16.79%
ACXP
Acurx Pharmaceuticals Inc.
$3.64-0.7  -16.13%
CGTX
Cognition Therapeutics Inc.
$3.50-0.64  -15.46%
HOOK
HOOKIPA Pharma Inc.
$1.50-0.26  -14.77%
CVAC
CureVac N.V.
$18.73-3.12  -14.28%
BFRI
Biofrontera Inc.
$3.47-0.53  -13.25%
BSGM
BioSig Technologies Inc.
$1.80-0.27  -13.04%
HCWB
HCW Biologics Inc.
$2.02-0.3  -12.93%
VRPX
Virpax Pharmaceuticals Inc.
$2.30-0.34  -12.88%
APM
Aptorum Group Limited
$1.48-0.21  -12.43%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ABBV – AbbVie Inc.
RINVOQ (Upadacitinib)
Atopic Dermatitis

$131.98
-1.05  -1%
Approved Approved January 14, 2022.
$233.3 billion

ALDX – Aldeyra Therapeutics Inc.
ADX-629
Psoriasis / atopic asthma / COVID-19

$3.25
-0.22  -6%
Phase 2 Phase 2 top-line data due by 1Q 2022.
$188.8 million

ALNY – Alnylam Pharmaceuticals Inc.
Vutrisiran
ATTR amyloidosis

$136.41
-1.90  -1%
PDUFA PDUFA date April 14, 2022.
$16.3 billion

ALNY – Alnylam Pharmaceuticals Inc.
Vutrisiran - (HELIOS-A)
ATTR Amyloidosis

$136.41
-1.90  -1%
Phase 3 Phase 3 primary and secondary endpoints met at 9 months, noted September 7, 2021. Phase 3 trial met all 18-month secondary endpoints, noted October 27, 2021. Full 18 month results reported a .46 mean decrease in Neuropathy Impairment Score and 1.2 point mean decrease in Norfolk QoL-DN score, noted January 21, 2022.
$16.3 billion

CRVS – Corvus Pharmaceuticals Inc.
CPI-818
Peripheral T-cell lymphoma (PTCL)

$1.77
-0.12  -6%
Phase 1/2 Phase 1b/2 trial initiated January 14, 2022.
$82.4 million

PFE – Pfizer Inc.
CIBINQO (abrocitinib)
Atopic Dermatitis

$52.79
-1.26  -2%
Approved Approved January 14, 2022.
$296.3 billion

PIRS – Pieris Pharmaceuticals Inc.
Cinrebafusp alfa (PRS-343)
Gastric cancer

$3.40
+0.06  +2%
Phase 2 Phase 2 trial first patient dosed, noted January 14, 2022. Phase 2 data expected in 2022, and data from cinrebafusp alfa in combination with ramucirumab and paclitaxel in 2023.
$245 million